Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. (PubMed, Neurology) - Oct 6, 2026 - "The study indicates that ofatumumab treatment is associated with a marginally increased relapse rate compared with ocrelizumab treatment in patients with RRMS. However, the ARR was very low with both anti-CD20 therapies, and the difference is of limited clinical relevance. Important limitations include the observational design and the risk of residual indication bias."
Clinical • Journal • Observational data • CNS Disorders • Multiple Sclerosis
|
|
; Arkadiusz Weglewski; Camilla Maersk-Moller; Christina Dahl Lindengren; Finn Sellebjerg; Henrik Boye Jensen; Hiba Alabdalridha; Jakob Schäfer; Jeppe Romme Christensen; Lucas Rundblad; Luigi Pontieri; Luke Karl Harper; Manuel Demirovic; Melinda Magyari; Morten Stilund; Peter Vestergaard Rasmussen; Sahla El Mahdaoui; Sepehr Mamoei; Tobias Sejbaek; Zsolt Illes
|